Addition of anti-disialoganglioside (GD2) chimeric mAb ch14.18, IL-2, and GM-CSF immunotherapy to 13-cis-retinoic acid improved event-free survival (EFS) for patients with high-risk neuroblastoma, but approximately 40 % still relapsed during or after this therapy [1]. This evidence concerns the gene IL2 and neuroblastoma.